文献速递基础与转化研究临床试验与 GCP

个体化癌症疫苗在卵巢癌中有效动员抗肿瘤T细胞免疫

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
PubMed 文献 · Sci Transl Med · 2018-01-01

一项试点临床试验在铂类治疗后的复发性卵巢癌患者中测试了负载氧化自体全肿瘤细胞裂解物的自体树突状细胞疫苗(OCDC),经淋巴结内注射。OCDC单用或联合贝伐珠单抗、贝伐珠单抗加低剂量环磷酰胺共给药392剂,无严重不良事件。疫苗接种诱导针对自体肿瘤抗原的T细胞反应,与显著延长生存相关,并扩增对新抗原的T细胞反应。

要点

  • OCDC疫苗在复发性卵巢癌中安全,392剂无严重不良事件。
  • 疫苗诱导的自体肿瘤抗原T细胞反应与显著延长生存相关。
  • 疫苗可扩增针对突变新抗原的T细胞反应,包括新克隆和高亲和力克隆。

核心结论

  • 氧化全肿瘤裂解物DC疫苗安全且能有效激发包括私有新抗原在内的广泛抗肿瘤免疫,值得进一步临床测试。

研究设计与样本

  • 试点临床试验,在铂类治疗后、免疫治疗初治的复发性卵巢癌患者中淋巴结内注射OCDC疫苗。
  • OCDC单用队列1(n=5),联合贝伐珠单抗队列2(n=10),联合贝伐珠单抗加低剂量静脉环磷酰胺队列3(n=10),直至疾病进展或疫苗耗尽。

主要发现

  • 共给药392剂疫苗,无严重不良事件。
  • 疫苗接种诱导针对自体肿瘤抗原的T细胞反应,与显著延长生存相关。
  • 疫苗扩增针对非同义体细胞肿瘤突变来源新抗原的T细胞反应,包括引发针对先前未识别新抗原的T细胞以及针对先前识别新抗原的高亲和力新T细胞克隆。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC was administered alone (cohort 1, n = 5), in combination with bevacizumab (cohort 2, n = 10), or bevacizumab plus low-dose intravenous cyclophosphamide (cohort 3, n = 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events. Vaccination induced T cell responses to autologous tumor antigen, which were associated with significantly prolonged survival. Vaccination also amplified T cell responses against mutated neoepitopes derived from nonsynonymous somatic tumor mutations, and this included priming of T cells against previously unrecognized neoepitopes, as well as novel T cell clones of markedly higher avidity against previously recognized neoepitopes. We conclude that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018. PMID: 29643231. doi:10.1126/scitranslmed.aao5931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。